5/18/2023 0 Comments Lily morton rule breakerWith a potential best-in-class clinical profile, Lilly plans on filing for donanemab's FDA approval later this quarter. That being said, there are key differences in the trials between these two drugs, making head-to-head comparisons impossible at this early juncture. What sparked this latest rally? Ahead of the opening bell, Lilly announced that its early-stage Alzheimer's disease treatment, donanemab, slowed cognitive decline by a clinically meaningful 35% in a late-stage trial.īy contrast, Biogen and Eisai's Food and Drug Administration (FDA)-approved Leqembi, slowed cognitive decline by 27% in a similar patient group, compared to placebo. Shares of the Illinois-based drugmaker Eli Lilly ( LLY -0.15%) were up by 6% on heavy volume as of 1:45 p.m.
0 Comments
Leave a Reply. |